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Effectiveness of COVID- 19 vaccines: findings 
from real world studies
Community- based studies in five countries show consistent strong benefits from early rollouts 
of COVID- 19 vaccines
By the beginning of June 2021, almost 11% of the world’s population had received at least one dose of a coronavirus disease 2019 (COVID- 19) 
vaccine.1 This represents an extraordinary scientific 
and logistic achievement — in 18 months, researchers, 
manufacturers and governments collaborated to 
produce and distribute vaccines that appear effective 
and acceptably safe in preventing COVID- 19 and its 
complications.2,3
The initial randomised trials confirmed 
immunological responses and generated unbiased 
evidence of vaccine efficacy. They were conducted 
in selected populations with limited numbers of 
participants in high risk groups, such as older 
people and those with serious underlying medical 
conditions.2,3 They provided sparse information on the 
impact of vaccination on transmission of severe acute 
respiratory syndrome coronavirus 2 (SARS- CoV- 2), 
were too small to quantify rare but serious harms, 
and did not take account of the logistic obstacles 
encountered during the community- wide rollout 
of new vaccines. While large cluster randomised 
trials could address some of these concerns,4 large 
observational studies have used large linked routinely 
collected population datasets in five countries to 
address important knowledge gaps.5- 9
This article reviews findings from the initial real world 
studies and stresses that researchers in Australia 
currently do not have timely access to the linked 
Commonwealth and state datasets needed to perform 
such analyses.
Real world studies
In five countries (Israel, England, Scotland, Sweden 
and the United States) researchers have analysed 
routinely collected data to report the early outcomes of 
community- wide vaccination programs with three of 
the first vaccines to reach market: the BNT162b2 mRNA 
(Pfizer– BioNTech), mRNA- 1273 (Moderna) and ChAdOx1 
adenoviral vector (Oxford– AstraZeneca) vaccines.5- 9
At the time of writing, two of the articles (from the 
US and Sweden ) have not yet been peer reviewed, so 
details reported here may change after revisions to 
these reports.8,9 There is a rapidly growing literature 
on the community impact of COVID- 19 and it has 
provided very consistent evidence of substantial 
vaccine effectiveness with the original (Wuhan) viral 
strain and the Alpha variant. An important focus 
of future work will be the effectiveness of existing 
vaccines against emerging viral variants.
The vaccination programs against COVID- 19 
commenced in December 2020 in the study countries, 
so follow- up is limited. Most of the investigators 
used rigorous designs and statistical methods to 
analyse linked routinely collected person- level data 
from large community- wide databases that tracked 
outcomes in vaccinated and unvaccinated individuals 
(Box). Importantly, allocation to vaccines was not by 
randomisation, and vaccinated and unvaccinated 
populations differed in respect of factors that were 
associated with both the probability of vaccination and 
with the severe outcomes of COVID- 19. Information 
that featured in most studies included demographic 
details, a vaccine register, results of laboratory 
polymerase chain reaction (PCR) testing, records 
of hospitalisation and death, and some geographic 
measures of social deprivation. In addition, the Israeli, 
US and Scottish studies included linkage to clinical 
records from which to quantify comorbidities.5,6,8 
The Israeli study included information on previous 
adherence to influenza vaccination schedules.5
Study designs and adjustments for confounding
The studies used different approaches to adjust for 
confounding (Box). The most advanced design was 
used to analyse the linked data from members of 
the Clalit Health Services integrated health care 
organisation in Israel, which covers around 4.7 million 
people.5 The investigators extracted data on matched 
cohorts of vaccinees and non- vaccinated controls and 
analysed study endpoints using rules that emulated 
the steps taken in a randomised trial.10 These steps 
minimised selection or measurement biases and 
controlled for potential confounders through precise  
1:1 matching of vaccinated and non- vaccinated subjects 
across seven domains. The investigators took the 
additional step of calibrating their statistical model 
against the results of the pivotal phase 3 randomised 
trial, which found no benefit during the first 2 weeks 
after vaccination.2 In contrast, this observational study 
found lower rates of infection in the first 2 weeks after 
vaccination, which remained after matching for age 
and sex — illustrating the potential for confounding. 
Only after full matching on seven factors was this 
source of bias eliminated.5
In England, investigators linked data from a national 
vaccine register to laboratory PCR swab results, 
emergency department admissions, demographic 
and ethnicity data, care home status, and deaths in 
participants aged 70 years and over (Box).7 The first 
part was a test- negative case– control design, which 
compared vaccination status in those who received 
a positive PCR swab result with contemporaneous 
controls who returned a negative result. That both cases 
and controls had been tested for SARS- CoV- 2 should 
have controlled for clinical and behavioural factors that 
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influence the probability of having a test. The second 
part of the study followed participants aged 80 years 
and over with a positive PCR test result and analysed 
them according to vaccination status. The investigators 
calculated adjusted hazard ratios for death up to and 
beyond 14 days from the first vaccine dose.
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1:1 matching on day of 
vaccination on seven 
features: age, sex, 
place, ethnicity, past 
influenza vaccine, 
pregnancy, number of 
pre- existing medical 
conditions
Adjusted for five 
features: age, sex, 
ethnicity, NHS region, 
deprivation
Adjusted for five 
features: age, sex, 
deprivation score, 
number of prior 
SARS- CoV- 2 PCR 
tests, number of 
medical conditions
Adjusted for age 
and sex
Propensity- matched 
based on sex, age, 
ethnicity, location and 
number of prior SARS- 
CoV- 2 PCR tests
Check on bias 
due to healthy 
vaccinee 
effect*
Yes, calibrated to 
check no effect in 
first 14 days
Yes, used immediate post 
vaccination period as 
reference
No, and significant 
benefit noted 
before day 14
No, did not 
evaluate endpoints 
before day 14
No, and significant benefit 






Days 14– 20: infection, 
46% (40– 51%); 
hospitalisation, 74% 
(56– 86%); death, 72% 
(19– 100%)
Days 28– 34 (BNT162b2): 
infection, 61% (51– 69%); 
hospitalisation† 43% 
(33– 52%); death,† 51% 
(37– 62%)




Day 14+: infection, 
42% (14– 63%); 
death not 
calculated‡
Day 14+: infection, 75% 
(67– 81%); hospitalisation 
60% (14– 79%)
Day 7+ after second 
dose: infection 
92% (88– 95%); 
hospitalisation, 87% 
(55– 100%)
Days 28– 34 (ChAdOx1): 
infection, 60% (41– 73%); 
hospitalisation† 37% 
(3– 59%)




Day 7+ after 
second dose: 
infection, 86% 
(72– 94%); death 
not calculated‡
Day 36+ (2 doses only); 
infection 89% (68– 97%)
Viral variants 
of concern
Alpha variant was 
common during the 
study
Alpha variant was 
dominant during the 
study
Alpha variant was 
common during the 
study
Alpha variant was 
common during 
the study
No mention of variants
BNT162b2 =Pfizer– BioNTech mRNA vaccine; ChAdOx1 = Oxford– AstraZeneca adenoviral vector vaccine; mRNA- 1273 = Moderna mRNA vaccine; NHS = National 
Health Service; PCR = polymerase chain reaction. * It is assumed that an apparent protective effect before day 14 reflects residual confounding. † Reductions in risk 
of hospitalisation and death were additional to the reduction in infection risk, equivalent to an overall reduction in hospitalisation of 80% and 85% reduction for 










A study in Scotland used an unmatched cohort 
design comparing hospital admission for COVID- 19 
in people who received either the Pfizer– BioNTech or 
Oxford– AstraZeneca vaccines with an unvaccinated 
control group.6 The Oxford– AstraZeneca vaccine 
was given later to an older population. The study 
adjusted for age and sex, frequency of prior PCR 
tests and clinical risk groups extracted from linked 
health records. The statistical model generated 
unexpectedly strong protective effects of the vaccines 
on hospitalisation rates in the first 2 weeks after 
vaccination, indicating possible bias due to a healthy 
vaccinee effect.
In the US, researchers working within the Mayo Clinic 
health system used postcode and propensity scores 
(based on age, sex, race, ethnicity and records of PCR 
testing) to match a cohort of individuals who received 
the Pfizer– BioNTech or Moderna mRNA vaccine with 
unvaccinated controls, to measure impact on infections 
and hospitalisations.8
A simple unmatched cohort design using linkage of 
routinely collected administrative data measured 
infection rates in a cohort who received the Pfizer– 
BioNTech vaccine in a single county in Sweden.9 The 
unvaccinated population acted as controls (Box). 
Confounding adjustments in this study were limited to 
age and sex.
The Box summarises the results of these studies. 
All included at least one mRNA vaccine and the 
reductions in infections and hospitalisations were 
consistent and large. Two studies reported on mortality 
and the reductions were substantial, although based 
on small numbers of deaths in Israel.5,7 The studies 
did not directly compare vaccines, but the Oxford– 
AstraZeneca vaccine appeared to perform as well as 
the mRNA vaccines in reducing hospitalisations.
Other approaches to estimating vaccine 
effectiveness
In the UK, over 600 000 volunteers using a COVID- 19 
symptom mobile phone app recorded adverse events 
after vaccination with either the Pfizer– BioNTech 
or Oxford– AstraZeneca vaccine.11 Based on post- 
vaccination self- reports of infections and after 
adjustment for age, sex, obesity and comorbidities, they 
estimated effectiveness rates of 60– 70% beyond 21 days 
after administration of either vaccine.
Three studies measured the effectiveness of COVID- 19 
vaccines in care home, health care and other frontline 
workers in the UK, Israel and the US.12- 14 These projects 
enrolled smaller numbers of participants than the 
community- based studies but used similar designs 
and adjustment techniques. Importantly, workers in 
these settings undergo routine PCR testing for SARS- 
CoV- 2, which enabled detection of asymptomatic 
infections. These studies also found large protective 
effects and a potential to reduce viral transmission. 
The latter possibility has been investigated directly in 
a study conducted in Scotland that showed that 14 days 
or more after health care workers received a second 
dose of vaccine, their household members had a 54% 
lower rate of COVID- 19 than individuals who shared 
households with non- vaccinated health care workers.15
Conclusions
We can draw important conclusions from these 
non- randomised studies of vaccine effectiveness. 
Most importantly, the currently available COVID- 19 
vaccines appear to be very effective in preventing 
severe complications and deaths from COVID- 19 in 
adults of all ages. Recent real world studies confirm 
that substantial protection extends to the Delta variant 
of SARS- CoV- 2, although this requires two vaccine 
doses.16,17 Follow- up periods in all studies are relatively 
short, and these reports do not provide information 
on rare but serious adverse events, such as cerebral 
venous thrombosis. The use of sophisticated trial 
emulation methods in the Israeli study5 replicated 
some key features of the pivotal randomised trial of the 
Pfizer– BioNTech vaccine,2 particularly by controlling 
for an early healthy cohort effect that confounded the 
incompletely adjusted endpoint analyses. This design 
should prove useful in enabling direct head- to- head 
comparisons of effectiveness and safety of vaccines, 
the duration of their protective effects, the degree to 
which vaccines prevent transmission of viral variants, 
and the impact of vaccines on so- called long COVID.
These studies exemplify the value of advanced 
analyses of large multiply linked routinely collected 
community datasets. This resource is not yet readily 
available to researchers in Australia due to continued 
lack of agreement on the governance of linked state 
and Commonwealth datasets.18 While Australia’s 
current low rates of community transmission of SARS- 
CoV- 2 reduce the feasibility of observational studies of 
vaccine effectiveness, the available data can provide 
important information on potential harms of vaccines. 
With continuing questions about the comparative 
safety of vaccines, the emergence of viral variants, the 
long term effects of COVID- 19 and the likelihood of 
future epidemics, it is essential that Australia urgently 
removes barriers to allowing prequalified researchers 
to safely access the linked de- identified population 
datasets that are needed to expeditiously conduct the 
types of studies reviewed here.
Competing interests: No relevant disclosures.
Provenance: Not commissioned; externally peer reviewed. ■
The unedited version of this article was published as a preprint on mja.
com.au on 20 May 2021.
© 2021 The Authors. Medical Journal of Australia published by John Wiley & Sons 
Australia, Ltd on behalf of AMPCo Pty Ltd.
This is an open access article under the terms of the Creative Commons 
Attribution-NonCommercial License, which permits use, distribution and repro-
duction in any medium, provided the original work is properly cited and is not used 
for commercial purposes.














 1 Our World in Data. Coronavirus (COVID- 19) 
vaccinations. https://ourwo rldin data.org/
covid - vacci nations (viewed May 2021).
 2 Polack FP, Thomas SJ, Kitchin N, et al. 
Safety and efficacy of the BNT162b2 
mRNA Covid- 19 vaccine. N Engl J Med 
2020; 383: 2603– 2615.
 3 Voysey M, Clemens SA, Madhi SA, et al. 
Single- dose administration and the 
influence of the timing of the booster 
dose on immunogenicity and efficacy of 
ChAdOx1 nCoV- 19 (AZD1222) vaccine: a 
pooled analysis of four randomised trials. 
Lancet 2021; 397: 881– 891.
 4 Bell KJL, Glasziou P, Stanaway F, et al. 
Equity and evidence during vaccine rollout: 
stepped wedge cluster randomised trials 
could help. BMJ 2021; 372: n435.
 5 Dagan N, Barda N, Kepten E, et al. 
BNT162b2 mRNA Covid- 19 vaccine in a 
nationwide mass vaccination setting. N 
Engl J Med 2021; 384: 1412– 1423.
 6 Vasileiou E, Simpson CR, Shi T, et al. 
Interim findings from first- dose mass 
COVID- 19 vaccination roll- out and 
COVID- 19 hospital admissions in 
Scotland: a national prospective  
cohort study. Lancet 2021; 397: 
1646– 1657.
 7 Bernal JL, Andrews N, Gower C, et al. 
Effectiveness of the Pfizer- BioNTech 
and Oxford- AstraZeneca vaccines on 
covid- 19 related symptoms, hospital 
admissions, and mortality in older adults 
in England: test negative case- control 
study. BMJ 2021; 373: n1088.
 8 Pawlowski C, Lenehan P, Puranik A, 
et al. FDA- authorized COVID- 19 vaccines 
are effective per real- world evidence 
synthesized across a multi- state health 
system [preprint]. medRxiv 2021; 27 
Feb. https://www.medrx iv.org/conte 
nt/10.1101/2021.02.15.21251 623v3 (viewed 
May 2021).
 9 Bjork J, Inghammar M, Moghaddassi M, 
et al. Effectiveness of the BNT162b2 
vaccine in preventing COVID- 19 in the 
working age population — first results 
from a cohort study in Southern Sweden. 
medRxiv 2021; 21 Apr. https://www.medrx 
iv.org/conte nt/10.1101/2021.04.20.21254 
636v1 (viewed May 2021).
 10 Hernán MA, Robins JM. Using big data to 
emulate a target trial when a randomized 
trial is not available. Am J Epidemiol 2016; 
183: 758– 764.
 11 Menni C, Klaser K, May A, et al. Vaccine 
side- effects and SARS- CoV- 2 infection 
after vaccination in users of the COVID 
Symptom Study app in the UK: a 
prospective observational study. Lancet 
Infect Dis 2021; 21: 939– 949.
 12 Hall VJ, Foulkes S, Saei A, et al. 
Effectiveness of BNT162b2 mRNA vaccine 
against infection and COVID- 19 vaccine 
coverage in healthcare workers in 
England, multicentre prospective cohort 
study (the SIREN Study) [preprint]. 
Preprints with The Lancet 2021; 22 Feb. 
https://papers.ssrn.com/sol3/papers.
cfm?abstr act_id=3790399 (viewed May 
2021).
 13 Amit S, Regev- Yochay G, Afek A, et al. 
Early rate reductions of SARS- CoV- 2 
infection and COVID- 19 in BNT162b2 
vaccine recipients. Lancet 2021; 397: 
875– 857.
 14 Thompson MG, Burgess JL, Naleway 
AL, et al. Interim estimates of vaccine 
effectiveness of BNT162b2 and mRNA- 
1273 COVID- 19 vaccines in preventing 
SARS- CoV- 2 infection among health care 
personnel, first responders, and other 
essential and frontline workers — eight 
US locations, December 2020– March 
2021. MMWR Morb Mortal Wkly Rep 
2021; 70: 495– 500.
 15 Shah AS, Gribben C, Bishop J, et al. 
Effect of vaccination on transmission 
of COVID- 19: an observational study 
in healthcare workers and their 
households [preprint]. medRxiv 2021; 
21 Mar. https://www.medrx iv.org/conte 
nt/10.1101/2021.03.11.21253 275v1 (viewed 
May 2021).
 16 Sheikh A, McMenamin J, Taylor B, 
Robertson C. SARS- CoV- 2 Delta VOC in 
Scotland: demographics, risk of hospital 
admission, and vaccine effectiveness. 
Lancet 2021; 397: 2461– 2462.
 17 Stowe J, Andrews N, Gower C, et al. 
Effectiveness of COVID- 19 vaccines 
against hospital admission with the 
Delta (B.1.617.2) variant [preprint]. 
London: Public Health England, 2021. 
https://media.tghn.org/artic les/Effec 
tiven ess_of_COVID - 19_vacci nes_again 
st_hospi tal_admis sion_with_the_
Delta_B._G6gnn qJ.pdf (viewed July 
2021).
 18 Henry D, Stehlik P, Camacho X, Pearson 
SA. Access to routinely collected 
data for population health research: 
experiences in Canada and Australia. 
Aust N Z J Public Health 2018; 42: 430– 
433. ■
